Last reviewed · How we verify
carboplatin periocular injection
Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill rapidly dividing cancer cells.
Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill rapidly dividing cancer cells. Used for Retinoblastoma (intraocular malignancy), Other intraocular tumors amenable to periocular chemotherapy.
At a glance
| Generic name | carboplatin periocular injection |
|---|---|
| Also known as | carboplatin, vincristine, carboplatin, etoposide |
| Sponsor | Sun Yat-sen University |
| Drug class | Platinum-based chemotherapy agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Carboplatin binds to DNA and forms interstrand and intrastrand crosslinks, preventing DNA replication and transcription in cancer cells. The periocular injection route delivers the drug directly to ocular tissues, allowing high local concentrations while minimizing systemic exposure. This is particularly useful for treating intraocular malignancies where systemic chemotherapy penetration is limited.
Approved indications
- Retinoblastoma (intraocular malignancy)
- Other intraocular tumors amenable to periocular chemotherapy
Common side effects
- Local inflammation/conjunctivitis
- Ocular irritation
- Systemic myelosuppression (if significant absorption)
- Cataract formation
Key clinical trials
- Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma (PHASE3)
- CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma (PHASE4)
- Carboplatin Periocular Injection for Retinoblastoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- carboplatin periocular injection CI brief — competitive landscape report
- carboplatin periocular injection updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI